# Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

> **NCT06759090** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 43 (estimated)

## Conditions studied

- Metastatic Pancreatic Carcinoma

## Interventions

- **DRUG:** Metronomic capecitabine
- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate Tablets

## Key facts

- **NCT ID:** NCT06759090
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759090, "Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06759090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*